<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The risks of <z:mp ids='MP_0000334'>agranulocytosis</z:mp> and <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> in relation to <z:chebi fb="29" ids="35480">analgesic</z:chebi> drug use were evaluated in a population-based case-control study conducted in Europe and Israel </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="29" ids="35480">Analgesic</z:chebi> use in the week before the <z:hpo ids='HP_0003674'>onset</z:hpo> of illness was compared between 221 cases of <z:mp ids='MP_0000334'>agranulocytosis</z:mp> and 1425 hospital controls </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="29" ids="35480">Analgesics</z:chebi> significantly associated with <z:mp ids='MP_0000334'>agranulocytosis</z:mp> were dipyrone (metamizol <z:chebi fb="199" ids="26708">sodium</z:chebi>), <z:chebi fb="0" ids="49662">indomethacin</z:chebi>, and butazones (phenylbutazone and oxyphenbutazone) </plain></SENT>
<SENT sid="3" pm="."><plain>For dipyrone, the rate ratio estimate was 23.7 in Ulm, West Germany, West Berlin, and Barcelona, Spain, and the estimated excess risk for any exposure in a one-week period was 1.1 per million </plain></SENT>
<SENT sid="4" pm="."><plain>In Israel and Budapest, Hungary, where the rate ratio estimate was 0.8, there was no evidence of excess risk </plain></SENT>
<SENT sid="5" pm="."><plain>In <z:hpo ids='HP_0000001'>all</z:hpo> of the regions combined, the rate ratio estimates were 8.9 for <z:chebi fb="0" ids="49662">indomethacin</z:chebi> and 3.8 for butazones, with excess risk estimates of 0.6 and 0.2 per million, respectively </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="29" ids="35480">Analgesic</z:chebi> use 29 to 180 days before admission was compared between 113 cases of <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> and 1724 controls </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="49662">Indomethacin</z:chebi> (rate ratio estimate, 12.7), <z:chebi fb="0" ids="4509">diclofenac sodium</z:chebi> (8.8), and butazones (8.7) were significantly associated with <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, with estimated excess risks for any exposure in a five-month period of 10.1, 6.8, and 6.6 per million, respectively </plain></SENT>
</text></document>